Supplemental Tables S2

<b>Aims: </b>Aurora kinase A (AURKA) has been implicated in promoting myeloid and renal fibrosis. This study aimed to investigate the impact and underlying mechanism of AURKA on liver fibrosis and to assess the therapeutic potential of MLN8237, a small-molecule AURKA inhibitor, in preventing liver fibrosis in mice.<b>Methods: </b>The research used bioinformatics analysis and immunohistochemistry staining on fibrotic liver tissues from human and mouse models to assess AURKA expression. The cellular localization of AURKA was determined through double immunofluorescence staining in human fibrotic liver tissues and primary mouse hepatic stellate cells. RNA interference and AURKA antagonism were used to examine the effects of AURKA on liver fibrosis, while RNA-sequencing, qRT-PCR, and western blotting were employed to elucidate the potential molecular mechanisms of AURKA on hepatic stellate cell activation.<b>Results: </b>The results showed that AURKA was positively correlated with the progression of liver fibrosis and mainly expressed in activated HSCs. Silencing AURKA inhibited HSC activation, proliferation and induced HSC apoptosis, similar to the effects of MLN8237 treatment. Additionally, silencing AURKA suppressed the glycogen synthase kinase-3beta/β-catenin signaling pathway. Pharmacological inhibition of AURKA phosphorylation also reduced liver fibrosis in vivo.<b>Conclusion: </b>In conclusion, AURKA may promote HSC activation and liver fibrosis through the Wnt/β-catenin pathway, suggesting its potential as a therapeutic target for liver fibrosis.